Program
Monday, October 19, 2020
- Opening Remarks and Opening Keynotes
- Plenary Session 1: Synthetic Biology and Novel Approaches to Immune Engineering
- Plenary Session 2: Innate and Adaptive Checkpoints
- Plenary Session 3: Novel Combinations
Tuesday, October 20, 2020
- Day 2 Keynote
- Plenary Session 4: Vaccines, Neoantigens, and Oncolytic Viruses
- Plenary Session 5: Non-T-Cell Therapies
- Plenary Session 6: T-Cell Therapies
- Plenary Session 7: Defining Novel Immunotherapy Targets
MONDAY, OCTOBER 19, 2020
OPENING REMARKS AND KEYNOTES
10-11:20 A.M.
Clinical development of BCMA-directed therapies in multiple myeloma
Kristen M. Hege, Celgene Corporation, San Francisco, California
A case for priming, not checkpoint
Robert H. Vonderheide, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Break
11:20-11:35 A.M.
Plenary Session 1: Synthetic Biology and Novel Approaches to Immune Engineering
11:35 A.M.-1:20 A.M.
Engineering artificial Antigen Presenting Complexes, aAPC, for cancer immunotherapy: From bench to bedside
Jonathan P. Schneck, Johns Hopkins University School of Medicine, Baltimore, Maryland
Additional speakers to be announced
Short talks from selected abstracts
Break
1:20-1:35 P.M.
Plenary Session 2: Innate and Adaptive Checkpoints
1:35 P.M.-3:35 P.M.
Targeting macrophages to promote anti-tumor immunity
Judith A. Varner, UCSD Moores Cancer Center, San Diego, California
Innate immune defenses against cancer: Potential for mobilizing NK cells for cancer immunotherapy
David H. Raulet, University of California, Berkeley, Berkeley, California
Additional speaker to be announced
Short talks from selected abstracts
Break
3:20-3:35 P.M.
Plenary Session 3: Novel Combinations
3:35-5:20 P.M.
Title to be announced
Charles G. Drake, Columbia University Irving Medical Center, New York, New York
The QuEST for an effective immunotherapy for prostate cancer
James L. Gulley, National Cancer Institute, Bethesda, Maryland
What are some different ways to evaluate immunotherapy combinations?
Michael Postow, Memorial Sloan Kettering Cancer Center, New York, New York
TUESDAY, OCTOBER 20, 2020
Day 2 Keynote Presentation
10-10:40 A.M.
Title to be announced
Laurie H. Glimcher, Dana-Farber Cancer Institute, Boston, Massachusetts
Break
10:40-10:55 A.M.
Plenary Session 4: Vaccines, Neoantigens, and Oncolytic Viruses
10:55-11:25 A.M.
Building improved personal cancer vaccines
Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts
Title to be announced
Adrian Hill, Jenner Institute at Oxford University, Oxford, England
Short talks from selected abstracts
Break
12:25-12:40 P.M.
Plenary Session 5: Non-T-Cell Therapies
12:40-2:10 P.M.
Title to be announced
Adrian C. Hayday, The Francis Crick Institute, London, England
The Future of CAR Therapies
Elizabeth J. Shpall, MD Anderson Cancer Center, Houston, Texas
Short talks from selected abstracts
Break
2:10-2:25 P.M.
Plenary Session 6: T-Cell Therapies
2:25-3:55 P.M.
Title to be announced
Avery D. Posey, University of Pennsylvania, Philadelphia, Pennsylvania
Title to be announced
Renier J. Brentjens, Memorial Sloan Kettering Cancer Institute, New York, New York
Short talks from selected abstracts
Break
3:55-4:10 P.M.
Plenary Session 7: Defining Novel Immunotherapy Targets
4:10-5:40 P.M.
Title to be announced
Arlene H. Sharpe, Harvard Medical School, Boston, Massachusetts
Probing the immune system in cancer
Stephen J. Elledge, Harvard Medical School, Boston, Massachusetts
Short talks from selected abstracts